Across TCGA pan-cancer cohorts, SOD3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SOD3 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SOD3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SOD3 expression acts as an unfavorable survival marker.
HNSC, LUSC, and SKCM are the cancer types where SOD3 Mutation most reproducibly stratifies survival.